142 related articles for article (PubMed ID: 35080187)
21. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
[TBL] [Abstract][Full Text] [Related]
22. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B
Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179
[TBL] [Abstract][Full Text] [Related]
23. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.
Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Motoi N; Yamamoto N; Ohe Y
Thorac Cancer; 2019 Apr; 10(4):815-822. PubMed ID: 30762312
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.
Mori R; Fujimoto D; Ito M; Tomii K
Oncotarget; 2017 Jul; 8(29):48521-48524. PubMed ID: 28591698
[TBL] [Abstract][Full Text] [Related]
25. AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
Zahn MO; Linck D; Losem C; Gessner C; Metze H; Gaillard VE; Tessen HW
BMC Cancer; 2019 May; 19(1):433. PubMed ID: 31077164
[TBL] [Abstract][Full Text] [Related]
26. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Massarelli E; Onn A; Marom EM; Alden CM; Liu DD; Tran HT; Mino B; Wistuba II; Faiz SA; Bashoura L; Eapen GA; Morice RC; Jack Lee J; Hong WK; Herbst RS; Jimenez CA
Clin Lung Cancer; 2014 Sep; 15(5):379-86. PubMed ID: 24913066
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
29. Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion.
Xu L; Wang B; Gao M; Zhang Y; Qi Q; Li T; Li C; Wang A; Li Y
Thorac Cancer; 2018 Aug; 9(8):950-955. PubMed ID: 29917319
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
[TBL] [Abstract][Full Text] [Related]
31. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
Front Immunol; 2021; 12():760683. PubMed ID: 34966384
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
33. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
Tohda Y; Iwanaga T; Takada M; Yana T; Kawahara M; Negoro S; Okishio K; Kudoh S; Fukuoka M; Furuse K
Chemotherapy; 1999; 45(3):197-204. PubMed ID: 10224342
[TBL] [Abstract][Full Text] [Related]
34. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S; Fukuda M; Yamaguchi H; Ikeda T; Akagi K; Tomono H; Umeyama Y; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Kitazaki T; Nakatomi K; Nagashima S; Fukuda M; Kinoshita A; Soda H; Mukae H
Thorac Cancer; 2020 Feb; 11(2):389-393. PubMed ID: 31851428
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
37. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
38. [Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer].
Gu LJ; Wang WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul; 26(7):1023-6. PubMed ID: 16864104
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
